New Drug Program Overview

Mindset is focused on developing novel IP and has developed a leading pipeline of pre-clinical psychedelic drug candidates derived from several differentiated patents describing a diversity of chemical structures optimized for pharmaceutical use

Family 1: Psilocybin-like prodrugs, substituted and deuterated analogs
  • Similar receptor binding and function profile to psilocybin
  • Orally active CNS penetrant
  • Lead Compound MSP-1014 selected
Family 2: Next-generation psilocybin optimized for in clinic setting
  • Improved receptor binding and function profile compared to psilocybin
  • Shorter acting, orally active CNS penetrant
Family 3: Next-generation psilocybin optimized for microdosing
  • Similar receptor binding and function profile to psilocybin
  • Long Duration of effect
Family 4: DMT/ 5-meO-DMT-inspired candidates
  • Currently performing in vitro screening